Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of 13.21 billion. The enterprise value is 9.88 billion.

Market Cap	13.21B
Enterprise Value	9.88B

Important Dates

The next estimated earnings date is Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.50M
Shares Outstanding	n/a
Shares Change (YoY)	-61.77%
Shares Change (QoQ)	+587.81%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	60.81M

Valuation Ratios

The trailing PE ratio is 11.59 and the forward PE ratio is 13.02.

PE Ratio	11.59
Forward PE	13.02
PS Ratio	4.09
PB Ratio	2.49
P/TBV Ratio	4.15
P/FCF Ratio	11.40
P/OCF Ratio	11.07
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.88, with an EV/FCF ratio of 8.53.

EV / Earnings	8.67
EV / Sales	2.83
EV / EBITDA	7.88
EV / EBIT	8.33
EV / FCF	8.53

Financial Position

The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.

Current Ratio	5.34
Quick Ratio	5.32
Debt / Equity	0.03
Debt / EBITDA	0.12
Debt / FCF	0.12
Interest Coverage	59.70

Financial Efficiency

Return on equity (ROE) is 22.80% and return on invested capital (ROIC) is 13.34%.

Return on Equity (ROE)	22.80%
Return on Assets (ROA)	11.54%
Return on Invested Capital (ROIC)	13.34%
Return on Capital Employed (ROCE)	18.83%
Revenue Per Employee	1.22M
Profits Per Employee	431,963
Employee Count	2,682
Asset Turnover	0.54
Inventory Turnover	11.54

Taxes

In the past 12 months, Genmab has paid 183.25 million in taxes.

Income Tax	183.25M
Effective Tax Rate	13.85%

Stock Price Statistics

The stock price has decreased by -14.03% in the last 52 weeks. The beta is 0.82, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.82
52-Week Price Change	-14.03%
50-Day Moving Average	208.38
200-Day Moving Average	211.15
Relative Strength Index (RSI)	57.24
Average Volume (20 Days)	42

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of 3.23 billion and earned 1.14 billion in profits. Earnings per share was 18.36.

Revenue	3.23B
Gross Profit	3.07B
Operating Income	1.10B
Pretax Income	1.32B
Net Income	1.14B
EBITDA	1.14B
EBIT	1.10B
Earnings Per Share (EPS)	18.36

Full Income Statement

Balance Sheet

The company has 3.23 billion in cash and 143.00 million in debt, giving a net cash position of 3.08 billion.

Cash & Cash Equivalents	3.23B
Total Debt	143.00M
Net Cash	3.08B
Net Cash Per Share	n/a
Equity (Book Value)	5.30B
Book Value Per Share	83.61
Working Capital	3.28B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.19 billion and capital expenditures -35.09 million, giving a free cash flow of 1.16 billion.

Operating Cash Flow	1.19B
Capital Expenditures	-35.09M
Free Cash Flow	1.16B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 95.12%, with operating and profit margins of 33.97% and 35.27%.

Gross Margin	95.12%
Operating Margin	33.97%
Pretax Margin	40.94%
Profit Margin	35.27%
EBITDA Margin	35.43%
EBIT Margin	33.97%
FCF Margin	35.87%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	61.77%
Shareholder Yield	61.77%
Earnings Yield	8.62%
FCF Yield	8.77%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.65 and a Piotroski F-Score of 5.

Altman Z-Score	9.65
Piotroski F-Score	5